These observations confirm the nature of NRASQ61 mutants to be more oncogenic as well as in vivo data that showed higher nevus and melanoma formation in NRASQ61R expressing p16INK4a-deficient mice [25]. This evidence concerns the gene CDKN2A and melanoma.